> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Delivers Mixed Vote on Lilly’s Cyramza
- URL: https://www.fdaweb.com/panel-delivers-mixed-vote-on-lillys-cyramza/
- Published: 2020-02-27T12:00:00.000Z
- Updated: 2026-09-14T16:04:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146200

FDA’s Oncologic Drugs Advisory Committee has delivered a mixed vote (six to five) to support approval of Eli Lilly’s supplemental BLA for Cyramza (ramucirumab) and its use in combination with Roche’s erlotinib for patients with untreated metastatic EGFR-positive non-small cell lung cancer. The panel based its vote on data from the Phase 3 RELAY study.

In the study, Cyramza, a VEGF receptor 2 antagonist, in combination with erlotinib, a globally approved EGFR-targeting tyrosine kinase inhibitor, showed a statistically significant and clinically meaningful improvement in progression-free survival compared to erlotinib alone, according to Lilly briefing materials. Median progression-free survival on the CYRAMZA-plus-erlotinib arm was 19.4 months compared to 12.4 months on the placebo-plus-erlotinib arm, it said.

On the safety side, the most common seious adverse events occurring at a higher rate on the Cyramza-plus-erlotinib arm compared to the placebo-plus-erlotinib arm were hypertension, dermatitis acneiform (an acne-like rash), and diarrhea.